1.060USD-0.93%Mkt Cap: 4.18M USDP/E: —Last update: 2026-05-26
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a pro…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap4.18M USD
Enterprise Value-9.13M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-8.91M USD
Revenue/Share—
Last Price1.060 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees8
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.39
PEG—
EV/EBITDA0.91
EV/Revenue—
P/S—
P/B0.33
EPS (TTM)-1.32
EPS (Forward)-2.77
52W Range
0.87501% of range32.16
52W High32.16 USD
52W Low0.8750 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-100.59%
ROA-76.96%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.27M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-129.24%
Net Debt-13.35M USD
Net Debt/EBITDA1.33
Balance Sheet
Debt/Equity0.08
Current Ratio10.02
Quick Ratio9.96
Book Value/Sh3.323 USD
Cash/Share3.611 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:4
Split DateJan 28, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)19.25 USD
Target Range16.00 USD – 22.50 USD
# Analysts2
Ownership
Shares Out.3.91M
Float3.44M
Insiders4.79%
Institutions12.78%
Short Interest
Short Ratio0.2d
Short % Float0.52%
Short % Out.0.49%
Shares Short18.41K
Short (prev mo.)54.96K
Technical
SMA 501.142 (-7.1%)
SMA 2003.944 (-73.1%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)72.67K
Avg Vol (10d)74.73K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—